Agios Pharmaceuticals Shares Rise on FDA Priority Review for Mitapivat in Sickle Cell Disease
Shares of Agios Pharmaceuticals surged by 13.8% this week after the FDA announced a priority review status for mitapivat, its key drug candidate targeting sickle cell disease (SCD). The decision follows mixed Phase 3 trial results where hemoglobin response and concentration were met but pain crisis reduction was not statistically significant.
Topics: drug approval process pharmaceuticals stock price movement